Literature DB >> 28728967

Impact of the Microbiota on Bacterial Infections during Cancer Treatment.

Jessica Galloway-Peña1, Chelcy Brumlow1, Samuel Shelburne2.   

Abstract

Patients being treated for cancer are at high risk for infectious complications, generally due to colonizing organisms that gain access to sterile sites via disrupted epithelial barriers. There is an emerging understanding that the ability of bacterial pathogens, including multidrug-resistant organisms, to colonize and subsequently infect humans is largely dependent on protective bacterial species present in the microbiome. Thus, herein we review recent studies demonstrating strong correlations between the microbiome of the oncology patient and infections occurring during chemotherapy. An increased knowledge of the interplay between potential pathogens, protective commensals, and the host immune system may facilitate the development of novel biomarkers or therapeutics that could help ameliorate the toll that infections take during the treatment of cancer.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; chemotherapy; infection; microbiome

Mesh:

Year:  2017        PMID: 28728967     DOI: 10.1016/j.tim.2017.06.006

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  13 in total

1.  The only thing that stops a bad microbiome, is a good microbiome.

Authors:  Jessica R Galloway-Peña; Robert R Jenq
Journal:  Haematologica       Date:  2019-08       Impact factor: 9.941

2.  Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection.

Authors:  Neslihan Kayraklioglu; Begum Horuluoglu; Madhivanan Elango; Dennis M Klinman
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

3.  Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia.

Authors:  Jessica R Galloway-Peña; Yushu Shi; Christine B Peterson; Pranoti Sahasrabhojane; Vancheswaran Gopalakrishnan; Chelcy E Brumlow; Naval G Daver; Mansour Alfayez; Prajwal C Boddu; Md Abdul Wadud Khan; Jennifer A Wargo; Kim-Anh Do; Robert R Jenq; Dimitrios P Kontoyiannis; Samuel A Shelburne
Journal:  Clin Infect Dis       Date:  2020-06-24       Impact factor: 9.079

4.  Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome.

Authors:  Lito E Papanicolas; Sarah K Sims; Steven L Taylor; Sophie J Miller; Christos S Karapetis; Steve L Wesselingh; David L Gordon; Geraint B Rogers
Journal:  BMC Cancer       Date:  2021-05-22       Impact factor: 4.430

5.  Evaluation of bloodstream infections, Clostridium difficile infections, and gut microbiota in pediatric oncology patients.

Authors:  Bryan T Nycz; Samuel R Dominguez; Deborah Friedman; Joanne M Hilden; Diana Ir; Charles E Robertson; Daniel N Frank
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

6.  A Case of Polymicrobial Bacteremia in a Patient Undergoing Chemotherapy.

Authors:  Kyoko Arahata; Ryo Yamaguchi; Takeshi Terashima
Journal:  Case Rep Infect Dis       Date:  2018-01-15

7.  Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study.

Authors:  Jessica R Galloway-Peña; Christine B Peterson; Farida Malik; Pranoti V Sahasrabhojane; Dimpy P Shah; Chelcy E Brumlow; Lily G Carlin; Roy F Chemaly; Jin Seon Im; Gabriela Rondon; Edd Felix; Lucas Veillon; Philip L Lorenzi; Amin M Alousi; Robert R Jenq; Dimitrios P Kontoyiannis; Elizabeth J Shpall; Samuel A Shelburne; Pablo C Okhuysen
Journal:  Open Forum Infect Dis       Date:  2019-04-04       Impact factor: 3.835

8.  Klebsiella pneumoniae prevents spore germination and hyphal development of Aspergillus species.

Authors:  M F Nogueira; L Pereira; S Jenull; K Kuchler; T Lion
Journal:  Sci Rep       Date:  2019-01-18       Impact factor: 4.379

9.  The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions.

Authors:  Jessica R Galloway-Peña; Dimitrios P Kontoyiannis
Journal:  PLoS Pathog       Date:  2020-04-02       Impact factor: 6.823

Review 10.  Pathogenetic Impact of Bacterial-Fungal Interactions.

Authors:  Filomena Nogueira; Shirin Sharghi; Karl Kuchler; Thomas Lion
Journal:  Microorganisms       Date:  2019-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.